Wednesday, July 8, 2026

pharma · Hyperphagia · Bariatric Surgery · AARD

Ark Therapeutics

Ark Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Boulder, USA HQ
2025 Founded
4 Employees
Public company Type
AARD · NYSE Ticker
Company details
Status
Public
HQ
Boulder, USA
Founded
2025
Employees
4
Programs
6
Drugs
5
Patents
7
Intelligence · Clinical Programs

Ark Therapeutics projects

6 ClinicalTrials.gov programs sponsored by Ark Therapeutics.

Ark Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ARD-101

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial
  2. Placebo

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial
  3. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial
  4. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial
  5. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial
  6. Low Dose ARD-501

    Ark Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Ark Therapeutics have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.